Auteurs
Checkpoint
Ncbi
Racine
Checkpoint
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Sarika Ogale »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Sarfraz Ahmad < Sarika Ogale < Sarka Fingerhutova  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000615 (2012) Vibeke Strand [États-Unis] ; Gerd R. Burmester ; Sarika Ogale ; Jenny Devenport ; Ani John ; Paul EmeryImprovements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
000A03 (2014) Edward C. Keystone [États-Unis] ; Andrew Anisfeld ; Sarika Ogale ; Jenny N. Devenport ; Jeffrey R. CurtisContinued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
000B57 (2014) Jeroen P. Jansen ; Felicity Buckley [États-Unis] ; Fred Dejonckheere ; Sarika OgaleComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
000D59 (2015) Josh J. Carlson [États-Unis] ; Sarika Ogale [États-Unis] ; Fred Dejonckheere [Suisse] ; Sean D. Sullivan [États-Unis]Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
001347 (2015) Stephen S. Johnston [États-Unis] ; Donna Mcmorrow [États-Unis] ; Amanda M. Farr [États-Unis] ; Paul Juneau [États-Unis] ; Sarika Ogale [États-Unis]Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic.
001353 (2015) Stephen S. Johnston [États-Unis] ; Donna Mcmorrow [États-Unis] ; Amanda M. Farr [États-Unis] ; Paul Juneau [États-Unis] ; Sarika Ogale [États-Unis]Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Sarika Ogale" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Sarika Ogale" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Sarika Ogale
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021